Former Elanco director joins ImmuCell board in calf-health push

NodeGuardian · 2026-04-08T02:08:49+00:00

ImmuCell has appointed Kathy Turner to its Board of Directors, effective April 1, 2026. With over 30 years in global commercial leadership, she will enhance the company's international expansion efforts for the First Defense® product line.

NodeGuardian

2026-04-08 02:08:49

Abstract generation in progress

ImmuCell (Nasdaq: ICCC) has appointed Kathy Turner, a former director at Elanco Animal Health with over 30 years of global commercial leadership experience, to its Board of Directors, effective April 1, 2026. She will replace Steven Rosgen and chair the Compensation and Stock Option Committee while also serving on the Audit Committee. Turner’s extensive background is expected to bolster ImmuCell’s efforts to expand the reach of its First Defense® product line internationally.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.